Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02621060
Recruitment Status : Completed
First Posted : December 3, 2015
Results First Posted : August 2, 2019
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
Esperanza Martínez-Abundis, University of Guadalajara

Brief Summary:
Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.

Condition or disease Intervention/treatment Phase
Impaired Glucose Tolerance Drug: Placebo Drug: Chlorogenic acid Phase 2

Detailed Description:

A randomized, double-blind, placebo-controlled clinical trial was carried out in 30 patients with a diagnosis of impaired glucose tolerance in accordance with the American Diabetes Association criteria. The patients received 400 mg capsules of Chlorogenic acid or placebo, three times daily 1/ 2 hour before meals for 90 days. Before and after intervention the investigators evaluated: 2 hours plasma glucose, glycated hemoglobin (A1C), triglycerides, high-density lipoprotein, fasting glucose and blood pressure body weight, body mass index, waist circumference, total cholesterol, low-density lipoprotein, very-low-density lipoprotein, creatinine, aspartate transaminase and alanine transaminase.

Were calculated: Areas under the curve of glucose and insulin were calculated with de Trapezoidal formula. Total insulin secretion was evaluated with the Insulinogenic index and the insulin sensitivity was estimated using the Matsuda index.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance
Study Start Date : September 2015
Actual Primary Completion Date : January 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
Drug: Placebo
Placebo: 1200 mg per day for three months
Other Name: Calcined magnesia

Experimental: Chlorogenic acid
1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
Drug: Chlorogenic acid
Chologenic acid: 1200 mg per day for three months
Other Name: 3-O-Caffeoylquinic, acid Heriguard




Primary Outcome Measures :
  1. Fasting Plasma Glucose (FPG) [ Time Frame: Week 12. ]
    Reflect the fasting glucose level after a 10- to 12-h overnight fast.

  2. 2 Hours Plasma Glucose (2-h PG) [ Time Frame: Week 12. ]
    Subjects underwent a 2-h oral glucose tolerance test (2-h OGTT) by consuming 75-g of a dextrose load, and one sample was obtained 120 min after glucose administration.

  3. Glycated Hemoglobin A1c (A1C) [ Time Frame: Week 12. ]
    Shows what a person's average blood glucose level was for the 2 to 3 months before the test high-performance.

  4. Total Insulin Secretion [ Time Frame: Week 12. ]
    After intervention. Total insulin secretion was calculated with the Insulinogenic index (Δ ABC insulin / Δ ABC glucose).

  5. First Phase of Insulin Secretion [ Time Frame: Week 12. ]
    After intervention with Stumvoll index

  6. Insulin Sensitivity [ Time Frame: Week 12. ]
    After intervention Matsuda Index


Secondary Outcome Measures :
  1. Area Under the Curve of Glucose [ Time Frame: Week 12. ]
    Area under the curve of glucose was obtained using the trapezoidal integration.

  2. Area Under the Curve of Insulin [ Time Frame: Week 12. ]
    Before and after intervention area under the curve of insulin

  3. Body Weight [ Time Frame: Week 12. ]
    The weight was measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the weight at week 12

  4. Body Mass Index [ Time Frame: Week 12. ]
    The Body Mass index was calculated at baseline and at week 12 with the Quetelet index and the entered values reflect the body mass index at week 12

  5. Waist Circumference (WC) [ Time Frame: Week 12. ]
    Waist circumference was evaluated at baseline and at week 12 with a flexible tape and the entered values reflects the waist circumference measure at week 12

  6. Systolic Blood Pressure (SBP) [ Time Frame: Week 12. ]
    The Systolic Blood Pressure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12

  7. Diastolic Blood Plessure (DBP) [ Time Frame: Week 12. ]
    The Diastolic blood plessure was evaluated at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12

  8. Triglycerides (TG) [ Time Frame: Week 12. ]
    The triglycerides were evaluated at baseline and week 12 with enzymatic-colorimetric techniques and the entered values reflect the triglycerides level at week 12

  9. Total Cholesterol (TC) [ Time Frame: Week 12. ]
    The total cholesterol was estimated by standardized techniques at baseline and week 12 and the entered values reflect the total cholesterol level at week 12

  10. High-density Lipoprotein Cholesterol (HDL-C) [ Time Frame: Week 12. ]
    The HDL-C levels were evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the HDL-C level at week 12

  11. Low-density Lipoprotein Cholesterol (LDL-C) [ Time Frame: Week 12. ]
    The LDL-C levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the LDL-C levels at week 12

  12. Very-low Density Lipoprotein (VLDL) [ Time Frame: Week 12. ]
    The VLDL levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the c-LDL levels at week 12

  13. Glutamic Pyruvic Transaminase (GPT) [ Time Frame: Week 12. ]
    Before and after intervention by spectrophotometry

  14. Glutamic Oxaloacetic Transaminase (GOT) [ Time Frame: Week 12. ]
    Before and after intervention by spectrophotometry

  15. Creatinine [ Time Frame: Week 12. ]
    The creatinine levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the uric acid levels at week 12

  16. Uric Acid [ Time Frame: Week 12. ]
    The uric acid levels were measured at baseline and at week 12 with standardized techniques and the entered values reflect the creatinina levels at week 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI: 30.0-34.99 kg / m2.
  • Diagnosis of IGT (OGTT Values between 140mg / dl and 199mg / dl.
  • Written informed consent.
  • Body weight stable over the last 3 months.
  • Women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests.
  • Women who are not contemplated get pregnant within the next 6 months.

Exclusion Criteria:

  • Women pregnant or breastfeeding.
  • Physical or mental disability that makes it impossible to perform the intervention.
  • Diagnosis of Hypertension or heart failure.
  • Smokers.
  • Untreated thyroid disease.
  • Consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering).
  • Diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes.
  • Diagnosis of renal disease or creatinine > 1.5 mg / dl.
  • Diagnosis of Type 2 Diabetes Mellitus (T2DM) Fasting glucose ≥ 126 mg / dL and/or OGTT ≥ 200 mg / dL and/or A1C ≥ 6.5%.
  • Total Cholesterol ≥ 280 mg/dL.
  • Triglycerids ≥ 300 mg/dL.
  • Known allergy to calcined magnesia or Chorogenic acid.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02621060


Locations
Layout table for location information
Mexico
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara
Guadalajara, Jalisco, Mexico, 44340
Sponsors and Collaborators
University of Guadalajara
Investigators
Layout table for investigator information
Study Director: Esperanza Martínez, PhD Science University of Guadalajara
Publications:

Layout table for additonal information
Responsible Party: Esperanza Martínez-Abundis, Researcher Professor, University of Guadalajara
ClinicalTrials.gov Identifier: NCT02621060    
Other Study ID Numbers: CT-ACG-271281-LYZ
First Posted: December 3, 2015    Key Record Dates
Results First Posted: August 2, 2019
Last Update Posted: August 2, 2019
Last Verified: June 2019
Keywords provided by Esperanza Martínez-Abundis, University of Guadalajara:
Chlorogenic acid
Control glucose
Insulin Secretion
Insulin Sensitivity
Additional relevant MeSH terms:
Layout table for MeSH terms
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Hyperglycemia
Magnesium Oxide
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents